Assays and Intrinsic Subtypes of Breast Cancer
Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses assays and intrinsic subtypes of breast cancer.
Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses assays and intrinsic subtypes of breast cancer.
The six intrinsic subtypes of breast cancer are luminal A, luminal B, HER2-enriched, basal-like, normal breast, and claudin-low. Though these subtypes are prognostic, Carey says, the way they inform treatment is a work in progress.
Several assays exist specifically to prognosticate the disease such as the 70-gene MammaPrint and the Oncotype DX Recurrence Score. A number of assays exist, though Carey notes that nothing is valid for ER-, HER2+ disease.
Clinical Pearls
The question remains as to how assays will be assessed regarding the information they give off and how pathways can be put together within a subtype, Carey says. In the future, physicians and researchers will molecularly characterize tumors and then use assays to get better information regarding treatment.
- There are six intrinsic subtypes of breast cancer: luminal A, luminal B, HER2-enriched, basal-like, normal breast, and claudin-low
- The way intrinsic subtypes inform treatment is a work in progress
- Carey believes that, in the future, physicians and researchers will molecularly characterize tumors and then use assays to get better information regarding treatment
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
